Lynette M. Sholl, MD
Testing for RET
aberrations is starting to gain importance in clinical practice along with the awareness that RET
fusions and mutations are drivers in multiple tumor types. In recent years, tyrosine kinase inhibitors that specifically target RET have entered the pipeline. Although none have yet received FDA approval, the promise of these agents has spurred interest in diagnostic assays that can accurately and efficiently detect RET
, in that something essentially leads to an abnormal event—for instance, when a fusion occurs—and that allows the tumor to propagate irrespective of external signals,” said Lynette M. Sholl, MD, an associate pathologist at Brigham and Women’s Hospital and associate professor at Harvard Medical School in Boston, Massachusetts.
Figure 1. RET Mutations are Common in Medullary Thyroid Cancer1
Figure 2. RET Fusions Occur in a Small Proportion of Tumors1
... to read the full story